InVision Precision Cardiac Amyloid vs MAGNETOM Cima.X

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

InVision Precision Cardiac Amyloid

by InVision Medical Technology Corporation

MAGNETOM Cima.X

by Siemens Medical Solutions USA

AI Verdict

Tool A, InVision Precision Cardiac Amyloid, is an AI-powered software designed to detect cardiac amyloidosis from echocardiography studies. Tool B, MAGNETOM Cima.X, is a 3T MRI system that uses AI for accelerated scans and deeper insights across various diseases, including cardiac conditions. While both utilize AI in cardiology, Tool A is a specialized diagnostic aid for a specific condition using echocardiograms, whereas Tool B is a broad imaging platform that can be used for various cardiac and other conditions via MRI.

Choose InVision Precision Cardiac Amyloid if…

Choose InVision Precision Cardiac Amyloid if your primary goal is the early and accurate detection of cardiac amyloidosis using echocardiography. This AI-powered software is specifically designed to integrate into existing echocardiography workflows, aiding clinicians in diagnosing and assessing patients with heart failure symptoms to reduce misdiagnosis and improve patient outcomes for both AL and ATTR Cardiac Amyloidosis.

View InVision Precision Cardiac Amyloid →

Choose MAGNETOM Cima.X if…

Choose MAGNETOM Cima.X if you require a high-performance 3T MRI system for comprehensive whole-body imaging, particularly for in-depth insights into oncologic, cardiac, and neurodegenerative diseases. Its powerful Gemini Gradients, AI-powered Deep Resolve, and BioMatrix technology are ideal for accelerating scans, adapting to patient variability, and providing unparalleled image quality for a wide range of complex diagnostic challenges.

View MAGNETOM Cima.X →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	InVision Precision Cardiac Amyloid	MAGNETOM Cima.X
Pricing	Subscription	Contact for pricing
Deployment	Software as a Medical Device (SaMD), integrated into clinical workflows for echocardiography labs.	On-premise
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

MAGNETOM Cima.X

MAGNETOM Cima.X emphasizes highly automated scan workflows with myExam Companion and BioMatrix Technology, which automatically adjusts to patient variability, suggesting a streamlined and intuitive user experience for technologists. InVision Precision Cardiac Amyloid integrates into existing clinical workflows for echocardiography labs, but its primary focus is on the diagnostic aid rather than overall workflow automation for image acquisition.

Clinical Value

MAGNETOM Cima.X

MAGNETOM Cima.X offers broader clinical value by providing deeper insights into oncologic, cardiac, and neurodegenerative diseases through its advanced 3T MRI system, stronger gradients, and accelerated scanning with Deep Resolve. InVision Precision Cardiac Amyloid, while crucial for early detection of cardiac amyloidosis, is a more specialized tool focused on a single disease within cardiology.

Pricing & Value

InVision Precision Cardiac Amyloid

InVision Precision Cardiac Amyloid offers transparent subscription pricing starting at $49/month, making its cost more predictable and accessible for individual labs or smaller practices. MAGNETOM Cima.X requires contacting Siemens Healthineers for pricing, indicating a higher, more complex, and likely enterprise-level investment, with estimated costs for a new 3T MRI installation ranging from $2.8M to $4.5M.

Enterprise Readiness

MAGNETOM Cima.X

Siemens Healthineers, as a large established medical solutions company, offers MAGNETOM Cima.X as an on-premise, high-end MRI system, implying robust enterprise-level deployment, support, and existing infrastructure integration within hospital systems. InVision Precision Cardiac Amyloid is a Software as a Medical Device (SaMD) integrated into clinical workflows, which suggests easier deployment but potentially less comprehensive enterprise-level infrastructure and support compared to a full MRI system.

Innovation

MAGNETOM Cima.X

MAGNETOM Cima.X showcases significant innovation with its Gemini Gradients (200 mT/m amplitude, 200 T/m/s slew rate), which are described as the strongest gradient system for a clinically released whole-body MR scanner, and its next-generation AI-powered Deep Resolve for accelerated scans. While InVision Precision Cardiac Amyloid utilizes AI for early disease detection, its innovation is focused on a specific diagnostic application within echocardiography rather than groundbreaking hardware advancements.

Support & Docs

Tie

Both companies are established in the medical field and are expected to offer comprehensive support and documentation for their respective products. However, specific details regarding the breadth and depth of support and documentation for each tool are not provided in the given information or readily available through general web searches to definitively pick a winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	InVision Precision Cardiac Amyloid	MAGNETOM Cima.X
Tool Name	InVision Precision Cardiac Amyloid	MAGNETOM Cima.X
Company	InVision Medical Technology Corporation	Siemens Medical Solutions USA
Description	AI-powered software for echocardiography to detect cardiac amyloidosis, a life-threatening and often underdiagnosed disease, aiming for earlier detection and improved patient outcomes.	Siemens Healthineers' strongest 3T MRI system, featuring AI-powered Deep Resolve, Gemini Gradients, and BioMatrix technology for unparalleled whole-body performance and deeper insights into oncologic, cardiac, and neurodegenerative diseases.
Starting Price	$49/mo	Not specified
Primary Clinical Focus	Cardiac amyloidosis detection via echocardiography	Oncologic, cardiac, and neurodegenerative diseases via 3T MRI
Key AI Features	AI-powered detection of cardiac amyloidosis, evidence-based AI algorithm	AI-powered Deep Resolve reconstruction technology, AI-powered myExam Companion workflow solution

Videos

Demos, reviews, and walkthroughs featuring InVision Precision Cardiac Amyloid and MAGNETOM Cima.X.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing cardiology workflows, and what is the learning curve for physicians and technologists?

InVision Precision Cardiac Amyloid is designed to integrate into echocardiography lab workflows, aiding clinicians in diagnosing and assessing patients with heart failure symptoms by evaluating transthoracic echocardiogram studies. MAGNETOM Cima.X, as a 3T MRI system, integrates into radiology workflows for various specialties, and its myExam Companion workflow solution, powered by AI, is designed to guide technologists, potentially simplifying its use.

What is the depth of EHR integration for each tool, and how does this impact data flow and accessibility for patient management?

InVision Precision Cardiac Amyloid is described as being integrated into clinical workflows for echocardiography labs, suggesting a level of data exchange relevant to patient studies. While MAGNETOM Cima.X focuses on image acquisition and reconstruction, its role as a diagnostic imaging system implies standard DICOM integration with PACS and, subsequently, EHR systems for image and report accessibility.

Can you elaborate on the accuracy and sensitivity of InVision Precision Cardiac Amyloid for detecting cardiac amyloidosis, and how does this compare to traditional diagnostic methods?

InVision Precision Cardiac Amyloid uses an evidence-based AI algorithm, peer-reviewed and published in JAMA Cardiology, to detect cardiac amyloidosis from echocardiograms, aiming for earlier detection and reduction of misdiagnosis. It supports the detection of both AL and ATTR Cardiac Amyloidosis and provides precise assessment of wall thickness.

Beyond the core functionalities, what specific security features are in place for each tool to protect patient data?

While both tools are HIPAA compliant, InVision Precision Cardiac Amyloid's description highlights its integration into clinical workflows, implying adherence to secure data handling practices within that context. For MAGNETOM Cima.X, as an on-premise MRI system, data security would typically involve the robust network and system security protocols established by the healthcare institution, in addition to the system's inherent security features.

What kind of customer support and training can be expected for each tool, and what resources are available for ongoing optimization and troubleshooting?

InVision Medical Technology Corporation offers InVision Precision Cardiac Amyloid as a subscription service, suggesting ongoing support. Siemens Healthineers, as a major medical device manufacturer, typically provides comprehensive training, service, and support for their MAGNETOM systems, including the Cima.X, to ensure optimal performance and address any technical issues.

Are there audit-trail features available in either tool to track usage, access, and changes to patient data or diagnostic interpretations?

While not explicitly detailed, as a Software as a Medical Device (SaMD) integrated into clinical workflows, InVision Precision Cardiac Amyloid would likely incorporate audit-trail capabilities to comply with regulatory requirements and ensure accountability in diagnostic processes. Similarly, advanced MRI systems like the MAGNETOM Cima.X, handling sensitive patient data and diagnostic information, are expected to have robust logging and audit-trail functionalities as part of their operating systems and associated software.

What considerations should be made for multi-site rollouts of these tools, particularly regarding consistency of results and technical support across different locations?

For InVision Precision Cardiac Amyloid, a multi-site rollout would involve consistent integration into echocardiography labs across different locations, ensuring standardized interpretation and support for the AI algorithm. For MAGNETOM Cima.X, multi-site deployment would require careful planning for installation, calibration, and ongoing maintenance of the physical MRI systems, along with standardized training and technical support across all sites to ensure consistent image quality and diagnostic capabilities.